Searching for ways to boost CAR-T response, Penn researchers find a capable wingman in BET inhibitors
A whole industry may have been born out of the spectacular success of CD19 CAR-T, pushing the envelope on next-generation constructs hitting new targets. But a group of researchers at the University of Pennsylvania reckons there’s still plenty of new things you can do with the OG cell therapy — with the help of a familiar class of drugs.
In doing so, they may have uncovered a way to get around T cell exhaustion, which has been a central challenge for the field.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.